A Randomized Two-Arm Trial of Prostate Cancer Patients Undergoing Active Surveillance With or Without MRI-Guided Management: The MGM Trial
Favorable risk patients will be randomized to one of two active surveillance arms.
Stratification will be based on Prostate-specific antigen density (PSAD) (=< 0.15 vs > 0.15
ng/mL per mL), and number of positive cores in the diagnostic biopsy (1 vs 2):
- Arm I: Active Surveillance Alone (AS). TRUS guided biopsies at start (within 6 months
of enrollment) and at yearly intervals thereafter up to 36 months after the initial
biopsy (maximum four biopsies).
- Arm II: MRI-Managed Active Surveillance (MRI-AS). MRIus or MRI-guided biopsies at start
(within 6 months of enrollment) and at yearly intervals thereafter up to 36 months
after the initial biopsy (maximum four biopsies).
Patients will also complete Quality of Life (QoL) assessments to provide unique data on the
effects of MRI monitoring for patients undergoing active surveillance on QOL. The
investigators have selected a group of measures that have been used extensively in prostate
Observational Model: Cohort, Time Perspective: Prospective
Rate of Progression in Subjects undergoing MRIus Biopsy vs Standard Ultrasound biopsy
To determine of multiparametric MRIus-guided biopsies increase the rate of progression on early (first two) biopsies in men undergoing active surveillance as compared with early detection using standard ultrasound biopsy.
Mark Soloway, MD
University of Miami Institutional Review Board
United States: Food and Drug Administration
|University of Miami Sylvester Comprehensive Cancer Center||Miami, Florida 33136|